全國服務咨詢熱線：
18860915427
18860915427
簡要描述：Moexipril hydrochloride 82586-52-5Moexipril HCl is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart fail
產品型號：abs47028317廠商性質：生產廠家更新時間：2026-01-29訪 問 量：1090產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 82586-52-5 |
|---|---|---|---|
| 分子式 | C27H34N2O7.HCl | 純度 | 98% |
| 分子量 | 535.03 | 貨號 | abs47028317 |
| 規格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | used for the treatment of hypertension | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
Moexipril hydrochloride 82586-52-5
| 產品描述 | |
| 描述 | Moexipril HCl is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart failure. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 鹽酸莫西普利；莫昔普利鹽酸鹽；RS-10085 |
| 外觀 | 白色粉末 |
| 可溶性/溶解性 | DMSO : 53.5 mg/mL (100 mM) water : 53.5 mg/mL (100 mM) |
| 生物活性 | |
| 靶點 | ACE |
| In vitro(體外研究) | Moexipril dose-dependently reduces the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+. Moexipril and enalapril attenuates staurosporine-induced neuronal apoptosis as determined by nuclear staining with Hoechst 33258. |
| In vivo(體內研究) | Moexipril (0.3 mg/kg) significantly reduces brain damage after focal ischemia as compared to control mice. Moexipril (0.01 mg/kg) is able to reduce the infarct volume in the rat model after focal cerebral ischemia. Moexipril reduces blood pressure after the first week of treatment but it has no apparent effect on either the proximal tibial metaphysis or the tibial shaft in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Moexipril combined with hydrochlorothiazide (HCTZ) exhibits a much more potent hypotensive effect and has the same effect on bone mass and dynamic end-points as HCTZ alone. Moexiprilat exhibits a higher inhibitory potency than enalaprilat against both plasma ACE and purified ACE from rabbit lung. Moexipril (0.1-30 mg/kg/day) lowers blood pressure and differentially inhibits ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. Moexipril (10 mg/kg/day) leads to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. |
| 參考文獻 | |
| 參考文獻 |
| 研究領域 | |
| 研究領域 | NeuroscienceEndocrine system Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：fengmj@univ-bio.com
傳真：